Clinical Data Viridian reports positive results from elegrobart phase 3 trial PharmaTimesCompany says treatment shows strong efficacy and convenient dosing profileClinical DataRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) PharmaTimes Company says treatment shows strong efficacy and convenient dosing profile Clinical DataRead full story Post navigation Previous: ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2DNext: FDA approves new high dose Spinraza regimen for SMA Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
